Cargando…
Cyclotron vs generator-produced 68Ga PSMA: a single-institution, prospective clinical trial
The clinical utility of gallium 68 ((68)Ga)-PSMA PET for the diagnosis and management of prostate cancer is driven in part by radioisotope availability and production costs. This study evaluates the equivalence between the two manufacturing processes for (68)Ga-PSMA: (68)Ga-PSMA-cyclotron (from a so...
Autores principales: | Martinez, Juana, Subramanian, Kritika, Castellanos, Sandra Huicochea, Thomas, Charlene, Choudhury, Arindam Roy, Muench, Brett, Tagawa, Scott T., Pillarsetty, Naga Vara Kishore, Osborne, Joseph R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Neoplasia Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9803810/ https://www.ncbi.nlm.nih.gov/pubmed/36571987 http://dx.doi.org/10.1016/j.tranon.2022.101593 |
Ejemplares similares
-
68Ga-PSMA-HBED-CC PET/MRI is superior to multiparametric magnetic resonance imaging in men with biochemical recurrent prostate cancer: A prospective single-institutional study
por: Martinez, Juana, et al.
Publicado: (2021) -
PSMA as a Theranostic Target in Hepatocellular Carcinoma: Immunohistochemistry and
(68)Ga‐PSMA‐11 PET Using Cyclotron‐Produced
(68)Ga
por: Thompson, Scott M., et al.
Publicado: (2021) -
Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020) -
(44)Sc-PSMA-617 for radiotheragnostics in tandem with (177)Lu-PSMA-617—preclinical investigations in comparison with (68)Ga-PSMA-11 and (68)Ga-PSMA-617
por: Umbricht, Christoph A., et al.
Publicado: (2017) -
In vitro and in vivo comparative study of a novel (68)Ga-labeled PSMA-targeted inhibitor and (68)Ga-PSMA-11
por: Chen, Huanyu, et al.
Publicado: (2021)